ethyl 2-bromo-4-chloro-7-methoxyquinoline-3-carboxylate | 1226760-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 2-bromo-4-chloro-7-methoxyquinoline-3-carboxylate
• CAS: 1226760-36-6
• 化学式: C₁₃H₁₁BrClNO₃
• 分子量: 344.592
• InChiKey: LYFNRMKLZCRSRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-bromo-4-chloro-7-methoxyquinoline-3-carboxylate 在 四(三苯基膦)钯 、 水 、 caesium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 46.5h， 生成 2-(dimethylamino)ethyl 7-methoxy-4-oxo-2-(3-phenoxyphenyl)-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z
• 作为产物：
  描述：

  7-甲氧基-4-氧代-1,4-二氢喹啉-3-羧酸乙酯 在 间氯过氧苯甲酸 、 三氯氧磷 、 三溴氧磷 作用下， 以 1,4-二氧六环 、 氯仿 为溶剂， 反应 6.0h， 生成 ethyl 2-bromo-4-chloro-7-methoxyquinoline-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials

  摘要：

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.

  DOI：

  10.1021/jm201642z

文献信息

• Synthesis and structure–activity relationships of antimalarial 4-oxo-3-carboxyl quinolones
  作者：Yiqun Zhang、W. Armand Guiguemde、Martina Sigal、Fangyi Zhu、Michele C. Connelly、Solomon Nwaka、R. Kiplin Guy

  DOI：10.1016/j.bmc.2010.02.013

  日期：2010.4

  while carrying out rationally directed low-throughput screening of potential antimalarial agents as part of an effort directed by the World Health Organization. Here we report the design, synthesis, and preliminary pharmacologic characterization of a series of analogues of 4-oxo-3-carboxyl quinolones. These studies indicate that the series has good potential for preclinical development.

  疟疾是非洲，亚洲和美洲的热带和亚热带地区的地方病。耐多药性恶性疟原虫的流行日益增加，因此不断需要开发新的抗疟药。鉴于此，特别感兴趣的是未暴露寄生虫的新型支架。最近，瑞士热带研究所的工作人员发现了两种新型的对恶性疟原虫的红细胞内阶段有活性的4-氧代-3-羧基喹诺酮类药物。同时根据世界卫生组织的指导，对潜在的抗疟药进行合理的定向低通量筛选。在这里，我们报告一系列4-氧代-3-羧基喹诺酮类似物的设计，合成和初步药理学表征。这些研究表明该系列药物在临床前开发方面具有良好的潜力。